Therapeutic targeting of the TGF-β pathway—particularly through inhibitors of integrins or downstream effectors like SOX4—offers promising potential for improving outcomes in aggressive breast cancer subtypes such as TNBC. The gene discussed is TGFB1; the disease is breast cancer.